StemCell Therapy

The Latest Research Report on Rheumatoid Arthritis Diagnosis Tests Market size | Industry Segment by Applications, by Type, Regional Outlook, Market Demand, Latest Trends, Rheumatoid Arthritis Diagnosis Tests Industry Share & Revenue by Manufacturers, Company Profiles, Growth Forecasts 2025. Analyzes current market size and upcoming 5 years growth of this industry.

According to the report, the Rheumatoid Arthritis Diagnosis Tests market is projected to register high demand during the forecast period with increasing demand from major end-use industries such as increasing demand due to growing inclination towards the use of renewable energy during the forecast period.

Click here to get sample of the premium report: https://brandessenceresearch.com/requestSample/PostId/316

A combined cycle power plant is a heat engine assembly that works in conjunction from the same heat source, converting it into mechanical energy that generally drives electrical generators in turn. The concept is that the operating fluid temperature in the system is still high enough after completing its cycle that a second subsequent heat engine extracts energy from the heat generated by the first engine.

With an emphasis on both organic and inorganic growth strategies, there have been several primary developments done by major companies include

Antibodies Inc., Euro Diagnostica AB, Qiagen NV, Siemens Healthcare GmbH, Bio Rad Laboratories Inc., Genway Biotech, Inc., Abbott Diagnostics, Beckman Coulter, Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc. and others.

Key Factors Impacting Market Growth:

o Increasing demand due to growing inclination towards the use of renewable energy.

o Strict government regulations directing various industries towards reducing their carbon footprint

o New developments in the clean energy sector, prompting companies to expand the horizon for CCGT market globally

Market Segmentation:

By Type:Serology TestsErythrocyte Sedimentation rateAnti-Cyclic Citrullinated PeptideRheumatoid FactorAntinuclear AntibodyUric AcidOthersMonitoring Rheumatoid Arthritis Treatment Efficiency TestsMuscle Enzyme TestsSalicylate Level CountCreatinine TestBy End-User:HospitalsDiagnostics LaboratoriesAmbulatory Surgical Centers

Request Customization of the premium report: https://brandessenceresearch.com/requestMethodology/PostId/316

Customization:

We provide customization of the study to meet specific requirements:

o By Segment

o By Sub-segment

o By Region/Country

Regional segmentation and analysis to understand growth patterns:

The market has been segmented in major regions to understand the global development and demand patterns of this market.

Detailed information for markets like North America, Western Europe, Eastern Europe, Asia Pacific, Middle East, and Rest of the World is provided by the global outlook for the Rheumatoid Arthritis Diagnosis Tests market. During the forecast period, North America and Western Europe are projected as main regions for the shortwave infrared sector. As one of the developed regions, the energy & power sector is important for the operations of different industries in this area.

This is one of the key factors regulating Rheumatoid Arthritis Diagnosis Tests market growth in those regions. Some of the major countries covered in this region include the USA, Germany, United Kingdom, France, Italy, Canada, etc.

During the forecast period, the Asia Pacific is expected to be one of the fastest-growing regions for the Rheumatoid Arthritis Diagnosis Tests market. Some of the fastest-growing economies and increasing energy & power demand to cater for high population & industries are expected to drive demand in this area. During the forecast period, China and India are expected to record large demand. During the forecast period, the Middle East which includes the UAE, Saudi Arabia, Iran, Qatar, and others promises high market potential. In terms of market demand during the forecast period, the rest of the world including South America and Africa are developing regions.

This report provides:

1) An overview of the global market for Rheumatoid Arthritis Diagnosis Tests market and related technologies.

2) Analysis of global market trends, yearly estimates and annual growth rate projections for compounds (CAGRs).

3) Identification of new market opportunities and targeted consumer marketing strategies for global Rheumatoid Arthritis Diagnosis Tests market.

4) Analysis of R&D and demand for new technologies and new applications

5) Extensive company profiles of key players in the industry.

The researchers have studied the market in-depth and have developed important segments such as product type, application, and region. Each and every segment and its sub-segments are analyzed based on their market share, growth prospects, and CAGR. Each market segment offers in-depth, both qualitative and quantitative information on market outlook.

Full Access to the Report: https://brandessenceresearch.com/requestSample/PostId/316

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Contact Us:

https://brandessenceresearch.biz/

Brandessence Market Research & Consulting Pvt ltd.,

Kemp House, 152 160 City Road, London EC1V 2NX

+44-2038074155

[emailprotected]

View post:
Cover Corona Outbreak: Rheumatoid Arthritis Diagnosis Tests Market 2020 Industry Growth Analysis, Segmentation, Size, Share, Trend, Future Demand And...

Compared with secukinumab, ixekizumab provides more quality-adjusted life-years (QALYs) to patients with psoriatic arthritis (PsA) and concomitant moderate to severe plaque psoriasis at a marginally lower cost, according to study results published in PharmacoEconomics Open.

In this study, investigators in the United Kingdom conducted cost-effectiveness analyses comparing ixekizumab and secukinumab, 2 interleukin-17A antagonist biologic disease-modifying antirheumatic drugs (bDMARDs) with similar treatment efficacy of PsA. Researchers sought to determine the treatment arm that achieved maximal clinical improvement while minimizing health costs to both patients and the healthcare system.

Using a Markov model, which is based on the York model, the investigators included a hypothetical cohort of adult patients with PsA and concomitant moderate to severe plaque psoriasis and simulated 4 health states, including a bDMARD trial period, continuous therapy, best supportive care, and death, along with 4 treatment options that aligned with UKs National Health Service (NHS) practice guidelines. The population and characteristics of patients were modeled from data derived from previous intent-to-treat trial populations. Data for each treatment arm were extrapolated from a network of meta-analysis for both therapeutics. Researchers used 2 clinical scoring criteria, including PsA Response Criteria and Psoriasis Area and Severity Index (PASI), to determine response to treatment. Quality of life was assessed using a health assessment questionnaire, and resource cost included treatment cost, physician visit, and medication administration costs, and an algorithm estimating the cost of care depending on the PASI and health assessment questionnaire scores.

Results indicated that ixekizumab vs secukinumab demonstrated slightly lower total costs of care and higher total QALYs in both bDMARD-naive and -experienced patients (155,455 vs 155,530 and 8.127 vs 7.989, and 140,051 vs 140,264 and 3.996 vs 3.875, respectively). Consistent results were derived from the various sensitivity analyses carried out in this model, which the researchers noted can be adapted to countries with reimbursement and treatment practices different to those in the UK.

Study limitations included lack of data availability since rheumatoid arthritis data were used for health resource cost estimates instead of PsA data, the use of therapeutic list pricing instead of the confidential preferred price used by the NHS, and the exclusion of data on patient preferences of treatment options.

Researchers concluded, Although total costs and QALYs were quite similar for ixekizumab and secukinumab, with a modest advantage to ixekizumab for both parameters in bDMARD-naive and -experienced patients with PsA and concomitant moderate to severe psoriasis, we believe the findings of our analysis still provide insights that may be helpful for healthcare decision-makers when allocating resources.

Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors disclosures.

Reference

Schweikert B, Malmberg C, kerborg , et al. Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab in the treatment of active psoriatic arthritis with concomitant moderate to severe psoriasis in the UK [published online on March 12, 2020]. Pharmacoecon Open. doi:10.1007/s41669-020-00202-1

Continue reading here:
Ixekizumab Superior to Secukinumab in Providing More Quality-Adjusted Life-Years in Psoriatic Arthritis - Rheumatology Advisor

Abdul Lone

By Josh Babcock, College of Veterinary Medicine

The next time a tick feeds on you, Washington State University researchers hope to make sure persistent arthritis caused by Lyme disease doesnt linger for a lifetime.

Troy Bankhead, associate professor in WSUs Veterinary Microbiology and Pathology department, and his team have spent more than a decade analyzing an immune evasive protein of Borrelia burgdorferi, the bacterium that causes tick-borne Lyme disease.

With the labs latest finding, that work is beginning to pay off.

According to research recently published in Cell Reports, Bankhead and assistant research professor Abdul Lone discovered that a surface protein known as VlsE acts as a shield to prevent the immune system from effectively fighting the disease. In particular, the study examined how VlsE protects one of the main proteins responsible for Lyme diseases persistent arthritis.

This really has a significant impact in the development of vaccines, Bankhead said.If we can determine which proteins are shielded as opposed to which ones are not, then of course those that are not protected are going to be better candidates for a vaccine.

The Centers for Disease Control and Prevention estimates some 300,000 people may get Lyme disease each year in the United States alone. It is most prevalent in the northeast.

If not treated early with antibiotics, Lyme disease can cause lifelong arthritis, and in more severe cases, bladder infections, heart inflammation, and neurologic and cognitive issues like loss of memory and balance.

We chose the arthritis-related protein because arthritis is the most common symptom you see in North America, Lone said.

By engineering a strain of Borrelia burgdorferi in the lab without the surface lipoprotein VlsE, they were able to confirm it was protecting the arthritis-related protein from an antibody response.

Bankhead and Lone tested the new Borrelia strain in mice and found the animals were more easily able to clear the infection.

Then, Bankhead and Lone confirmed that the new Borrelia strain was susceptible to antibodies under the microscope.

By using fluorescence microscopy, a process that uses energy from electrons to emit light under a microscope, Bankhead and Lone watched as antibodies were unable to bind to the protein responsible for Lymes persistent arthritis when the VlsE protein was present. When the VlsE protein was removed, antibodies were able to recognize and bind to the arthritis-related protein.

When you dont have VlsE those bacteria light up and that is because those antibodies are able to bind and recognize that arthritis-related protein in the absence of that VlsE shield, Bankhead said. Thats exactly what we were seeing.

Understanding the VlsE protein is acting as a shield for the bacteriums arthritic-causing protein is significant for vaccine development and future research. While it is unknown if other surface proteins are protected, Bankhead said it is likely. He noted the scientific community is gaining ground on understanding these proteins but producing any vaccine is well into the future.

Still, the finding creates two avenues for researchers to eliminate Lyme disease: take down the VlsE shield, or, find a way for the antibody response to get in front of the ever-adapting bacterium and eliminate it.

HIV/AIDS persists for years in human beings. The same thing happens with Borrelia, it persists, Lone said. While this finding tells us a lot about Borrelia. Our next step is to understand how it persists. Once we understand the mechanism of persistence, we can eliminate the disease.

Read the original:
Cracking the Lyme disease code - WSU News

Global Arthritis Therapeutics Market was valued USD XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of 4.8 % during forecast period of 2019 to 2026.

The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.Arthritis is an inflammatory disorder affecting the joints cause redness, stiffness, resulting in pain and swelling in the joints. More than 100 categories of arthritis are affecting the global population. The most common arthritis conditions are psoriatic arthritis, rheumatoid arthritis, and osteoarthritis. The osteoarthritis affects a majority of the geriatric population, in severe joint pain and affecting their movement. Psoriatic Arthritis therapeutics contains drugs that help to reduce pain and inflammation.

REQUEST FOR FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/request-sample/36112

Global Arthritis Therapeutic Market Drivers and RestrainsThe significant growth of the global arthritis therapeutics market is credited to investments in research & development, strong product pipeline, increasing patient pool suffering from arthritis. Furthermore, rise in the geriatric population is another factor fueling the growth of the global arthritis therapeutics market. Patients gone under treatment with Disease-Modifying Antirheumatic Drugs (DMARDs) are unsatisfied because of poor therapeutic benefits. The dominance of rheumatoid arthritis globally, the launch of novel therapeutic agents, and favorable reimbursement policies for high-cost treatment products are the factors that boost the growth of global arthritis therapeutics market. In 2016, the International Federation of Psoriasis Association (IFPA) states that more than 125 Mn people were affected with psoriasis. It is estimated that between 11% and 32% of patients with psoriasis incline to develop psoriatic arthritis. Furthermore, nearly 52.2 million adults suffered from arthritis in U.S. alone in 2015. Developments in diagnostics and healthcare infrastructure in developing countries are projected to witness an increased number of diagnosed patients.

Manufacturers in the Arthritis Therapeutic are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.

Global Arthritis Therapeutic Market Segmentation AnalysisBy Arthritis Therapeutic Market is segmented into Psoriatic Arthritis, Rheumatoid Arthritis, Osteoarthritis, Gout and Others. Rheumatoid Arthritis and Psoriatic Arthritis segment is expected to exhibit highest global market share at a CAGR of xx% over forecast period. Increasing occurrence of arthritis diseases globally, is likely to drive key players to develop novel therapeutics treatment for the disease. Strong research and development by key companies supported by huge investments is projected to drive the global arthritis therapeutics market. In 2018, according to the WHO statistics 9.9 % of men AND 18.1 % of women over the age of 60 suffered from osteoarthritis, symptomatic, worldwide. About 80 % of those with osteoarthritis have limitations in movement, and 25 % of women over the age of 60 suffered from symptomatic osteoarthritis, globally.

Global Arthritis Therapeutic Market Regional AnalysisThe Global Arthritis Therapeutic Market has been classified into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East Africa. North America dominated the global arthritis therapeutics market, followed by Europe. Because of a large patient pool suffering from arthritis diseases, like osteoarthritis, rheumatoid arthritis and other conditions. Advantageous reimbursement policies, launching of novel biologics drugs, well-defined regulatory framework, and availability of biosimilars are boost up the market growth in the region. Furthermore, the presence of key players in the region and a strong product pipeline for arthritis treatment are projected to drive the arthritis therapeutics market in the region. This can be ascribed to awareness about arthritis, presence of key players, growing patient pool, favorable reimbursement policies, and availability of biosimilar and biologics arthritis drugs in the region.

The objective of the report is to present comprehensive analysis of Global Arthritis Therapeutic Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding Global Arthritis Therapeutic Market dynamics, structure by analyzing the market segments, and project the Global Arthritis Therapeutic Market size. Clear representation of competitive analysis of key players by Arthritis Therapeutic Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Arthritis Therapeutic Market make the report investors guide.

DO INQUIRY BEFORE PURCHASING REPORT HERE: https://www.maximizemarketresearch.com/inquiry-before-buying/36112

Scope of the Global Arthritis Therapeutic Market

Global Arthritis Therapeutic Market, by Type

Psoriatic Arthritis Rheumatoid Arthritis Osteoarthritis Gout OthersGlobal Arthritis Therapeutic Market, by Drug Class

TNF Inhibitors Interleukin Inhibitors NSAIDs Corticosteroids Xanthine Oxidase Inhibitors OthersGlobal Arthritis Therapeutic Market by Route of Administration

Oral Parenteral TopicalGlobal Arthritis Therapeutic Market, by Distribution Channel

Hospital Pharmacies Retail Pharmacies Online PharmaciesGlobal Arthritis Therapeutic Market, by Region

Asia Pacific North America Europe Latin America Middle East AfricaGlobal Arthritis Therapeutic Market, Major Players

Pfizer Inc. Bristol Myers Squibb Abbvie Inc. Astrazeneca Pharma Ucb Pharma Genentech Janssen Pharmaceutical Immunex Corp. Medac Pharma Boehringer Ingelheim Novartis, Biogen Eli Lilly And Company Astellas Pharma Mallinckrodt Roche Vertex Pharmaceutical

MAJOR TOC OF THE REPORT

Chapter One: Arthritis Therapeutic Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Arthritis Therapeutic Market Competition, by Players

Chapter Four: Global Arthritis Therapeutic Market Size by Regions

Chapter Five: North America Arthritis Therapeutic Revenue by Countries

Chapter Six: Europe Arthritis Therapeutic Revenue by Countries

Chapter Seven: Asia-Pacific Arthritis Therapeutic Revenue by Countries

Chapter Eight: South America Arthritis Therapeutic Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Arthritis Therapeutic by Countries

Chapter Ten: Global Arthritis Therapeutic Market Segment by Type

Chapter Eleven: Global Arthritis Therapeutic Market Segment by Application

Chapter Twelve: Global Arthritis Therapeutic Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Arthritis Therapeutic Market Report at: https://www.maximizemarketresearch.com/market-report/global-arthritis-therapeutic-market/36112/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

View original post here:
Global Arthritis Therapeutic Market: Industry Analysis and forecast (2019 to 2026): By Type, Drug Class, Route of Administration, Distribution Channel...

People often deal with the discomfort of osteoarthritis by taking over-the-counter nonsteroidal anti-inflammatory drugs. Over time, if the pain worsens, they may find themselves taking those drugs in regular, increasing doses. That isnt good for older people, Polk experts say.

Your fingers feel stiff.

Parts of your hands often hurt.

Simple acts like opening a jar become more difficult or painful.

Its highly possible these problems stem from osteoarthritis of the hands.

Half of women and one-fourth of men experience osteoarthritis hand stiffness and pain by the time they reach 85, according to the Arthritis Foundation.

"Hand arthritis is extremely common in women," said Dr. Stuart Patterson, an orthopaedic surgeon in South Lakeland who specializes in disorders of the hand and other parts of the upper limb.

"We see it in men, but it typically occurs earlier in women."

People often deal with the discomfort initially by taking over-the-counter nonsteroidal anti-inflammatory drugs. Over time, if the pain worsens, they may find themselves taking those drugs in regular, increasing doses.

That isnt good for older people, local hand experts said.

"Once you get into your 60s, theyre not a safe drug," Patterson said.

"There are many interactions between these meds and supplements, as well as blood thinners (prescription as well as aspirin)," Dr. Ann Licht said in an email response to a question about whether its OK to rely on NSAIDS.

"People with high blood pressure and kidney problems may have more severe reactions to NSAIDS," added Licht, a Watson Clinic surgeon specializing in hand surgery.

Osteoarthritis is most common in the small joints of the fingers, closest to the nails and the base of the thumb, Licht said. It can occur on one side and spread to the other.

Gnarly fingers, bumps, finger deformities, joint stiffness and bone formations, often called bone spurs, are some physical signs that occur in advanced osteoarthritis of the hand, Patterson said.

Osteoarthritis causes protective cartilage at the end of bones to break down and wear away. Pain occurs as the bones rub together.

Surgery isnt all these surgeons and other hand specialists have to offer when that happens.

"Surgery is when youre disabled, either disabling pain or impairing your ability to do things," Patterson said, "when youre miserable and youve exhausted your non-surgical options."

Its helpful to see a hand surgeon before that stage to rule out other causes of pain, such as rheumatoid arthritis or carpal tunnel syndrome, he said.

Licht recommends seeing a hand specialist when medicines dont work, arent indicated or when deformities are starting.

"Steroid injections to the joints can be a lifesaver for patients who are either not ready for surgery cant take arthritis meds or the meds arent working," Licht said.

Occupational therapists have an important role in treating osteoarthritis of the hand. They work with patients on hand exercises, devices like splints or braces and pain relief such as warm paraffin.

Some therapists, mostly occupational but also some physical therapists, take extra training to become certified hand therapists.

"Our main goal in hand therapy is to preserve the hand," said Jennifer Castelli, occupational and certified hand specialist. "We focus on what they need and adapt it from there."

If a joint is overworked, it causes tension in the tissue around it, affecting the amount of pain. Joint damage also occurs.

Splints can keep the joint from moving so it has time to rest, Castelli said.

She and her husband, John, founded The Hand Rehabilitation Center of Florida. It has clinics in Winter Haven, Lakeland and Sebring.

Their Lakeland clinic has connecting space with Pattersons Central Florida Orthopaedic Surgery Associates. Patterson collaborates with Judie Johnson, another of the rehabilitation centers occupational therapists/certified hand specialists.

"Getting people in here early, before they develop horrible stiffness and horrible pain can help them learn helpful management skills," Johnson said.

Hand therapists can offer a variety of alternatives, including exercises to increase the hands range of motion and ways to do everyday activities that put less stress on the joints. Examples would be avoiding doing heavy pinching with the thumb and lifting pots with two hands instead of one, Johnson said.

Assistive devices can make it easier to open jars or hold a spoon.

"It doesnt fix the arthritis but it makes it so you hopefully can live with it," said Johnson, who has dealt with hand osteoarthritis of her own for 20 years.

Hand specialists can help "cut through the confusion" of the volume of devices and tools to find the ones most effective for individual patients, Patterson said.

"Even if two people have the same type of arthritis, their needs and medical history/conditions may make treatment very different," Licht said.

"Evaluation by a qualified hand surgeon can offer options and treatment solutions tailored to the individual."

When surgery is needed, patients and their surgeons decide between fusion or joint replacement. Which works best depends on the location of the damaged joint and, to some extent, what patients need to do with their hands.

Patterson said joint replacement doesnt do well in the small joints at the end of the fingers. He prefers fusion for them.

But fusion typically doesnt do as well at the base of the thumb, he said, or in the middle joint of the long and ring fingers. Those middle joints, he said, need to be able to bend and fusion prevents that.

Overall, joints are best fused if they arent "vital motion" joints, Licht said, while some need to be replaced to preserve or improve motion.

"Fusions are most reliable and require minimal rehab," she said. "Joint replacements require a compliant/committed patient as (they) usually require several months of rehab."

Robin Williams Adams can be reached at robinwadams99@yahoo.com

See original here:
Polk doctors: Hand pain, stiffness from osteoarthritis can be treated - The Ledger

Researchers have taken positive steps towards using plant virus-based particles for the treatment of human autoimmune diseases such as type 1 diabetes and rheumatoid arthritis.

Viruses are natural, self-assembling nano-scale structures that have been exploited in the fields of electronics, agriculture and medicine.

The genetically encoded coat proteins of virus nanoparticles (VNPs) can be reprogrammed to incorporate new sequences for specific functions. Plant viruses have the advantage in that they are unable to replicate in mammals making them safer for medical applications.

In this study led by the University of Verona, Italy, researchers explored whether VNPs engineered to display a specific protein sequence could help to prevent or treat type 1 diabetes and rheumatoid arthritis.

They used cowpea mosaic virus (CPMV) constructs developed in the Lomonossoff lab at the John Innes Centre. These VNPs displayed peptides associated with type 1 diabetes in order to modulate immune system response. The researchers also used other VNPs, engineering tomato bushy stunt virus with peptides associated with rheumatoid arthritis.

Using animal models to analyse immune system responses, they reveal that the re-engineered nanoparticles offered therapeutic benefits in both cases: protection against type 1 diabetes and improved symptoms of rheumatoid arthritis.

More pre-clinical and clinical trials will follow up this work. If successful it could pave the way for the development of plant viruses for the clinical treatment of human autoimmune diseases.

The research: Prevention and treatment of autoimmune diseases with plant virus nanoparticles appears in Science Advances.

Link:
Plant viruses could be used to prevent and treat human autoimmune diseases - Mirage News

Here are the top stories recently covered by DocWire News in the Rheumatology section. In this edition, read about trials of rheumatoid arthritis (RA) drugs to treat COVID-19 patients, how rheumatic patients were affected during the early pandemic days, how the coverage gap closure in Medicare Part D between 2010 and 2019 decreased annual out-of-pocket costs for RA biologics, and an interview about the Autoimmune COVID-19 Project.

The results of a French study found favorable outcomes for COVID-19 patients with moderate to severe pneumonia treated with tocilizumab, a drug commonly prescribed to treat arthritis, according to reports. The French CORIMUNO-TOCI trial was conducted by the public assistance-hospitals of Paris (AP-HP). The results have yet to be published, but the outcomes were reported in a press release and by various news outlets. The main outcome measure was the need for ventilation or death at 14 daysfor which tocilizumab significantly reduced the risk. CORIMUNO is exploring other medicines in COVID-19 patients, too, including sarilumab. Although both are anti-IL-6 drugs, tocilizumab is administered intravenously, while sarilumab is administered subcutaneously. The results of a phase 2 trial studying sarilumab in COVID-19 patients found the drug was not beneficial for patients hospitalized but not on ventilators, according to results from Regeneron and Sanofi, who manufacture the drug.

A study evaluated how patients with rheumatic diseases were impacted by the COVID-19 pandemic during its initial stages in the United States. A total of 7,061 patients were invited to complete the questionnaire, of whom 530 responded. The most common diagnosis among the respondents was rheumatoid arthritis (RA) (61%). Of the 11 patients who met COVID-19 screening criteria, two sought testing unsuccessfully. An additional six patients sought testing, of whom three were successful, and all were negative. About two in five patients (42%) experienced a change to their care during the previous two weeks. Upon qualitative analysis, the researchers unearthed four key themes: emotions in response to the pandemic, perceptions of risks from immunosuppressive medications, protective measures to reduce risk of COVID19 infection, and disruptions in accessing rheumatic disease medications including hydroxychloroquine.

A new study assessed whether the coverage gap closure in Medicare Part D between 2010 and 2019 decreased annual out-of-pocket costs for biologic drugs used to treat RA. Each year, list prices increased for every product assessed in the drug and strength combinations. There were six drugs available for the whole study period; the mean increase for these drugs was 160%. Among the six drugs available for the entirety of the study, the projected mean annual out-of-pocket costs were 34% lower in 2011 than 2010 (2010: $6,108 vs. 2011: $4,026); however, they were only 21% lower by 2019 ($4,801) due to yearly list prices increases. There were four products with higher out-of-pocket costs in 2019 than the first year available that entered the market between 2011 and 2015. The percentage of money spent in the catastrophic phase increased each year for all products studied; the mean was 22% higher in 2019 than in 2010 or the first year the drug was available.

CreakyJoints and the Global Healthy Living Foundation collectively launched the Autoimmune COVID-19 Project, a longitudinal study with the goal of assessing the impact of COVID-19 on patients with multiple sclerosis, arthritis, Crohns and colitis, and vasculitis. DocWire News recently interviewed study lead Shilpa Venkatachalam, PhD, associate director of Patient-Centered Research at CreakyJoints and co-principal investigator of ArthritisPower, about the studys inception, its goals, and more.

Continued here:
Rheum Round-up: Are Arthritis Drugs the Holy Grail of COVID-19?, How The Pandemic Affected Rheumatic Patients, and more - DocWire News

The word arthritis derives from the Latin arthro meaning joint and ritis meaning inflammation.

There are broadly two main types of arthritis although one can classify 100 different types. The two main types are the degenerative (wear and tear) and the inflammatory types of arthritis.

Arthritis can affect any age group, not just the elderly. Juvenile inflammatory arthritis can be a disabling illness in young children.

In the vast majority of cases, degenerative arthritis is primary i.e. with no preceding cause. In rare cases, however, degenerative arthritis may be secondary to a fracture of the joint, infection or inflammation.

Arthritis can affect any joint; but those most commonly affected by degenerative arthritis are the hip, knee, neck and back.

The patient suffers from a variety of symptoms which may develop and progress over time into degenerative arthritis.

In contrast, in inflammatory arthritis, these symptoms may develop suddenly. The symptoms include pain which usually worsens with activity and stiffness mostly in the morning and following inactivity which might be accompanied by swelling. In advanced cases, there will be deformity and muscle-wasting. The symptoms cause lack of function of the joint and disability.

Diagnosis is aided by radiological investigations which, in degenerative disease, show loss of joint space, sclerosis which is whitening of the bones and bony projections called osteophytes. Interestingly, there is not always a direct correlation between the severity of radiological findings and the symptoms described.

Diagnosis is aided by radiological investigations which, in degenerative disease, show loss of joint space, sclerosis which is whitening of the bones and bony projections called osteophytes

Treatment of arthritis broadly falls into four categories:

1. Weight loss for lower limb arthritis, routine and regular exercise and physiotherapy helps build muscle, decrease stiffness, decrease pain and also improve psychological well-being. Cycling, swimming and the cross-trainer are ideal for hip, knee and foot arthritis.

2. Medications include cartilage-nutrient supplements such as glucosamine and chondroitin. Medications including anti-inflammatories shouldnt be prescribed on a long-term basis due to side effects. They should be used to allow the patient to exercise and undertake regular physiotherapy.

3. Other options for treatment include injections. There are principally three types of injections I use. These are not all necessarily adapted for each arthritic joint.

While steroid injections are a mixture of a local anaesthetic and steroid injected directly into the joint, viscosupplementation involves injecting a thick viscous fluid in the joint which is thought to act as a shock absorber.

On the other hand, PrP or platelet rich plasma involves extracting about 15ml of blood from the patient, centrifuging it and injecting the fluid left without the cells into the joint. This plasma contains nutrients and other factors that help regenerate cartilage, prevent its breakdown and decrease inflammation.

4. Surgery remains the best option for those patients who fail to improve with the other options. Different surgical techniques are adapted for different joints but broadly, these may include washout of the joints by keyhole or arthroscopic techniques. Examples of these techniques include excision of the joint (excision arthroplasty) such as the collar bone joint; fusion of the joint (arthrodesis) such as the foot big-toe joint and replacement (arthoplasty).

In the latter, the arthritic joint is excised and replaced by a metal and plastic artificial joint. In fact, most joints in the body may be replaced including the small joints of the hand, wrist, elbow, shoulder and, of course, hip and knee. Although these are fairly major procedures, the benefit they provide to the patients quality of life is tremendous.

Alistair Pace is a consultant orthopaedic surgeon and senior lecturer at the University of Malta.

Independent journalism costs money. Support Times of Malta for the price of a coffee.

Read this article:
How to deal with arthritis - Times of Malta

(BPT) Arthritis joint pain is a daily reality for millions of people in the United States. For some, this pain is temporary due to an injury, but for others, it can be a persistent and even debilitating symptom of arthritis.

Osteoarthritis is the most common form of arthritis, according to the Centers for Disease Control and Prevention, affecting more than 30 million adults in the United States1. About one in four adults report experiencing severe joint pain related to arthritis, and nearly half of adults with arthritis experience persistent pain2.

Whether your arthritis pain is temporary or ongoing, its important to take steps to alleviate discomfort. We may not realize how much joy comes from the simplest everyday movements, until pain gets in the way. Here are four simple tips that may help lessen your arthritis joint pain so you can feel better and keep moving.

1. Use hot and cold therapy

Applying hot and cold compresses to your joints can help provide some much-needed relief. When joints feel stiff, use heat to help them relax and feel more agile. A morning bath or shower can make a world of difference for stiff joints after sleeping. For joint pain that involves swelling and inflammation, look to incorporate cold therapy into your routine. For instance, if your knee is sore and looks puffy, apply a cold compress or bag of frozen veggies wrapped in a towel.

2. Move your body

If you have arthritis symptoms, including wrist, hand or knee pain, the idea of getting up and exercising may seem counterintuitive. However, thoughtfully moving your body helps increase blood flow to joints and stretches muscles and ligaments, which can provide some relief. Regular movement helps increase flexibility while also building muscle, which is important for the health of the joints.

3. Use over-the-counter medicines

If you want an alternative to taking pills to manage pain, there is now an effective topical arthritis pain relief solution available without a prescription. The FDA recently approved Voltaren Arthritis Pain as the first and only full prescription-strength topical nonsteroidal anti-inflammatory (NSAID) gel available over the counter for the treatment of arthritis pain in adults in the hand, wrist, elbow, foot, ankle or knee. Visit http://www.voltarengel.com/what-is-voltaren/ now to preorder Voltaren Arthritis Pain (available nationwide next month). If you order now through May 12, 100% of profits from pre-order will be donated to the Arthritis Foundation to provide virtual care and connection for their patient community*. Additionally, for every donation made to the Arthritis Foundation between May 13 and May 31 in support of its goal to provide virtual care and connection to their patient community and mission, Voltaren will match up to $100,000.

4. Add glucosamine and omega-3s to your diet

Fish oil has been studied for dozens of inflammatory and autoimmune disorders, according to the Arthritis Foundation3. You can get the omega-3s by taking a high-quality fish oil supplement. Look for fish oil options with at least 30% EPA and DHA (both types of omega-3s). According to the Arthritis Foundation, taking up to 2.6 grams EPA/DHA twice a day may help relieve osteoarthritis pain.

If arthritis joint pain is a part of your life, try these simple strategies at home to help movement so you can live a full, healthy life.

More:
Simple tips and tricks to help manage arthritis pain - Defiance Crescent News

Dear family and friends,

I have rheumatoid arthritis (RA), a chronic autoimmune disease. Its not the wear-and-tear type of arthritis you might get with old age. This is different. It affects my whole body and chips away at my well-being. To be honest, Im still figuring it out myself. One thing I do know is that it will affect not just my life, but also yours. I want to help you understand how it feels to be me. If you know the basics, we have a place to start a conversation.

Remember the last time you had the flu? You felt sick and feverish, your body was hurting, and you were so tired that the idea of making a cup of tea or taking a shower was completely overwhelming.

RA makes me feel like that. This illness happens when the immune system malfunctions. Instead of protecting me against infection, it gets confused and attacks tissues and structures in my body. Arthritis in my joints is one of the symptoms, but being an autoimmune disease means it affects my entire body. Thats what makes me feel like I have the flu all the time. Sometimes, it gets better, usually through taking medications, but its no guarantee. RA can flare unpredictably, all my symptoms increasingsometimes a little, sometimes taking over my life. I have figured out a few triggers to the symptoms, but often, theres no rhyme or reason to why I flare. Often, there is no visible sign of the war inside my body. I need your support.

RA causes inflammation that affects all parts of my body, but the way it hits my joints is the most obvious symptom. Im sure youve seen my sausage fingers or noticed the time my knee swelled to the size of a volleyball. Its because the synovial membrane that protects my joints becomes inflamed.

And it hurts.

I thought I knew what it meant to have pain before. We have all had some lower back pain after moving to a new house, a sprained ankle, and maybe even broken a bone. None of those kinds of pain is like the pain of RA. When my joints swell, it can feel as if the bones are being pried apart. When the inflammation gets bad, it throbs to the rhythm of my heart and any weight or pressure is excruciating. Every step feels like walking barefoot on rocks, typing for a while means I cant use my hands later, and it can make it hard to do the simplest of tasks. Like dressing myself, squeezing the shampoo bottle, or chopping vegetables.

Yes, I know everyone is tired. But this kind of tired doesnt get better with rest. The fatigue that comes with having RA is always there, utterly soul-crushing, and it doesnt matter if I get two hours of sleep at night or 12. Im still tired. My body is in a constant state of inflammation and keeps trying to get me to go lie down until I get better.

The problem is, I dont get better.

I wake up with less energy than I had before and everything I do takes more energy than it used to. The Spoon Theory is a really good way to explain how careful I have to be about what I do and why sometimes, I have to crawl into bed before dinner. Think of measuring energy by the spoonful. I start the day with a handful of spoons that are taken away, one by one, as I do tasks like getting dressed, doing chores, or working. Most days, I have no spoons left at the end of the day.

I used to only see my doctor a few times a year. Now, I have medical appointments all the time. Blood tests, X-rays, ultrasounds, appointments with my family doctor (because RA makes it easier for me to catch colds and the flu), and regular appointments with my rheumatologist, who oversees my RA treatment.

I am taking medication to suppress this condition, to protect my joints and the rest of my body against the constant inflammation. Please dont try to persuade me to go off the meds because you think the chemicals are bad for me. Its really hard to take this much medication every day, and sometimes, it has side effects. But it does beat down my RA most of the time and I want thatI cant live my life without them.

Some of the medication I take may include one that suppresses my immune system, and therefore suppresses my RA. This means I have a much higher risk of infection and catching contagious illnesses. One of the best ways you can help me is by getting the flu shot and not coming over when youre sick. Between the RA and being on these drugs, if I get sick, it might hit me harder and take a lot longer for me to get better.

Everything about my life has changed and I am having a really hard time coping. I feel like the healthy me died and now instead, I have to learn to live in this body that has betrayed me. There are so many physical changes, so much time dedicated to medical appointments, and figuring out how to fit all of that into my life. Everything feels overwhelming.

I know Im not always coping well. To be honest, I am really sad and also really angry. Im doing my best to learn what to do so I can still be your family member and your friend, but Im struggling. I know its hard for you to understand it all and that its difficult watch me go through this. I need your help, but please dont try to fix me. Right now, the thing I need the most is your love, patience, and support. I need some hugsgentle ones, pleasesome laughs, and some practical help. A phone call or visit would be wonderful, maybe a freezer meal, a ride to the doctor, or help with some chores. But most of all, I need you to just listen and try to understand.

Original post:
Dear Loved Ones: This Is What RA Feels Like - HealthCentral.com

The results of a French study found favorable outcomes for COVID-19 patients with moderate to severe pneumonia treated with tocilizumab, a drug commonly prescribed to treat arthritis, according to reports.

The French CORIMUNO-TOCI trial was conducted by the public assistance-hospitals of Paris (AP-HP). The results have yet to be published, but the outcomes were reported in a press release and by various news outlets. It included patients who were hospitalized with COVID-19 moderate to severe pneumonia in intensive care or at high risk of requiring intensive care but did not need resuscitation upon admission. The study included 129 patients who were randomized to either usual treatment plus tocilizumab (n=65) or usual treatment alone (n=64). The main outcome measure was the need for ventilation or death at 14 daysfor which tocilizumab significantly reduced the risk.

The unpublished study will reportedly be submitted for journal publication. According to a press release, the researchers stated that the results must be peer-reviewed and confirmed in further trials, but given the emergent need created by the pandemic, they felt it was important to communicate the results.

CORIMUNO is exploring other medicines in COVID-19 patients, too, including sarilumab. Although both are anti-IL-6 drugs, tocilizumab is administered intravenously, while sarilumab is administered subcutaneously.

The results of a phase 2 trial studying sarilumab in COVID-19 patients found the drug was not beneficial for patients hospitalized but not on ventilators, according to results from Regeneron and Sanofi, who manufacture the drug.

The trial of sarilumab, manufactured and sold under the brand name Kevzara, was modeled off of a 21-person study in China of tocilizumab, which optimistically concluded that patients symptomsincluding feverwere significantly reduced and they were able to be discharged from the hospital. With these promising outcomes in mind, Regeneron and Sanofi moved rapidly to evaluate Kevzara in a prospective, randomized, placebo-controlled adaptively-designed U.S. Phase 2/3 trial, according to a press release from the companies.

Even in a pandemic setting, its both crucial and possible to obtain controlled data in adequately-sized trials to provide the evidence needed to inform optimal medical care, said George D. Yancopoulos, MD, PhD, co-founder, president, and chief scientific officer of Regeneron, in the release. Emerging evidence with Kevzara and other repurposed drugs in the COVID-19 crisis highlight the challenges of making decisions about existing medicines for new viral threats using small, uncontrolled studies. We await results of the ongoing Phase 3 trial to learn more about COVID-19, and better understand whether some patients may benefit from Kevzara treatment. In addition, there is an acute need for tailored approaches that specifically target this virus. To that end, Regeneron is rapidly advancing our targeted anti-SARS-CoV-2 antibody cocktail and we plan to initiate clinical trials in June.

The New York Times reported that Dr. Yancopoulos was not optimistic about the trial because the drugs in questioned were made to treat arthritis, not COVID-19.

Repurposing existing drugs has not had a history of success in the pharmaceutical industry, he reportedly said.

Here is the original post:
Are Arthritis Drugs the Holy Grail of the COVID-19 Pandemic? Trials Rush to Find Solutions - DocWire News

Dry eye and subclinical abnormalities in visual functions in patients with psoriatic arthritis (PsA) sine-psoriasis may be related to systemic inflammation, according to study results published in the Journal of Clinical Medicine.

In this noninterventional, cross-sectional study, the disease activity of patients aged 18 to 65 years with diagnosed PsA and no evidence of skin psoriasis (n=40) was assessed by an experienced rheumatologist; a healthy control group (n=35) was also included in the study. All patients received a standard ophthalmology exam, which included best-corrected visual acuity, ocular surface disease index questionnaire, Schirmer test, and tear film breakup time (BUT). Standard automated perimetry, spectral-domain optical coherence tomography, and fundus perimetry scans were performed in all patients.

Researchers evaluated 80 and 70 eyes from patients in the PsA group (72.5% women; mean age, 5214 years) and the healthy control group (60% women; 48.713.8 years) , respectively. The best-corrected visual acuity of patients in the PsA group and the healthy control group were similar, and an abnormal ocular surface disease index (OSDI) was observed in 60% of patients with PsA. Prevalence of dry eye was significantly greater in the PsA group compared with the healthy control group (P <.0001). Approximately 75% of patients in the PsA group (n=30) were definitively diagnosed with dry eye (39.9% with BUT <10 sec; 23.4% with Schirmer 5 mm; 36.7% with both BUT <10 sec and Schirmer 5 mm).

Researchers indicated a positive correlation between OSDI and erythrocyte sedimentation rate (ESR; r=0.6; P <.001), In terms of the Schirmer test values, a negative correlation was observed between the scale of wetness and ESR (r=-0.43; P =.007). Results from standard automated perimetry indicated a higher mean deviation and pattern standard deviation in the PsA group compared with the healthy control group (P <.0001 and P =.005, respectively). In addition, ESR and C-reactive protein (CRP) showed a positive association with pattern standard deviation (r=0.3 and r=0.4; P =.04 and P =.01, respectively), while CRP was also correlated with mean deviation (r=-0.4; P =.01). Patients with PsA and the control participants demonstrated a similar visual field index (range, 98%-100%).

Assuming that relevant signs of systemic disease may be revealed as abnormalities occurring in the eye, a clinical evaluation of retinal morphology and function should be performed in order to detect subclinical damage of the visual system early, the researchers advised. In addition, careful ophthalmologic examination of patients with PsA sine-[psoriasis] may produce valuable clinical information on disease activity status. Using either [standard automated perimetry] or [fundus perimetry] and [optical coherence tomography] assessment could allow the detection of early changes in visual function even before clinically detectable retinopathy. These ancillary tests may serve as a useful monitoring tool over the entire course of the disease.

Reference

Chimenti MS, Triggianese P, Salandri G, et al. A multimodal eye assessment in psoriatic arthritis patients sine-psoriasis: evidence for a potential association with systemic inflammation. J Clin Med. 2020;9(3):E719.

See original here:
Visual Functions in Psoriatic Arthritis Sine-Psoriasis May Be Linked to Systemic Inflammation - Rheumatology Advisor

While there are drugs that help reduce the symptoms of rheumatoid arthritis in the joints, those medications can have unpleasant side effects in other parts of the body. An experimental new light-based system, however, is being designed to change that.

One of the problems with existing rheumatoid arthritis drugs lies in the fact that after they've been ingested or injected, they're distributed throughout (and are active within) the entire body. This means that if they're taken in the quantities needed to reduce inflammation of the joints, they may produce side effects such as stomach aches or insomnia.

If they could only become active when they were at the joints, then much smaller doses would be required, resulting in fewer side effects. That's where the new system comes in.

Developed by scientists at the University of North Carolina in Chapel Hill, it involves attaching an existing drug to specially-engineered vitamin B12 molecules. Those molecules are then loaded into red blood cells, which get injected into the bloodstream.

As long as those cells aren't subsequently exposed to long-wavelength tissue-penetrating laser light, the drug remains trapped and inactive within them for up to two hours. If a laser is held to the skin at an arthritic joint, however, even low levels of its light within that joint trigger the nearby B12 molecules to release their drug payload from within the red blood cells. As a result, the medication only kicks in once it's at the target joint.

In lab tests, the technology was successfully used to deliver the arthritis drug dexamethasone to the arthritic paws of mice. When compared to simply injecting pure dexamethasone straight into the bloodstream, the laser-activated system required a three-fold lower dose to achieve the same therapeutic effect.

"We hope that our drug delivery platform will better control drug delivery and decrease the amount of systemic exposure and off-target effects," says team member and doctoral candidate Emilia Zywot. "We envision that it will be useful for any drug that can be synthetically attached to our light-responsive system, making it amenable to applications beyond arthritis."

The abstract for a paper on the research was recently published in The FASEB Journal.

Source: Experimental Biology via EurekAlert

More here:
Laser light used in targeted treatment of arthritis - New Atlas

As GlaxoSmithKline prepares Voltaren Arthritis Pain for a sizable prescription-to-OTC switch next month, a new pre-order promotion will donate to the Arthritis Foundation.

Through May 12, the official Voltaren OTC availabilityday in the U.S., customers can order the NSAID osteoarthritis gelto getfirst-day at-home delivery through GSK Consumer Healthcare e-commerce partners. Profits from the sales will go to the Arthritis Foundation.

The awareness-buildingand pre-order effort is underway as behind the scenes, GSK is fine-tuning Voltarens prescription to OTC priority launch marketing push that will include TV, print, radio, in-store, digital and social advertising.

FiercePharma Presents the Virtual eRegulatory Operations Summit

Join industry experts and learn how to build and manage cohesive, compliant, and timely electronic submissions through innovative technologies and seamless clinical documentation processes.

RELATED:GSK looks for another OTC allergy crossover hit in newly launched Flonase Sensimist

GSK has the benefit of lessons learned from the Flonase allergy nasal spray prescription to OTC launch several years ago, said Jissan Cherian, Voltaren marketing director.Many of the same executives are still at GSK Consumer Healthcarechief marketing officer Amardeep Kahlon, in fact, oversaw the Flonase switch in 2015and while e-commerce has changed since then, other strategies have carried over.

In-store promotions, for instance, will follow the Flonase lead and use custom display units to educate consumers at point of sale, Cherian said. The multi-channel and extensive ad campaign looks to beanother nod to the Flonase model.

The campaign will seek to expand the Voltaren audience based on GSK research that found osteoarthritis begins for some people in their 30s. Without revealing specific creative, Cherian said a range of ages and life stages will be featured and that the brand will look to establish itself as a movement brand. The Voltaren website will be a first-ever for arthritis patients, created to be user friendly for their specific hand movement issues, he said.

RELATED:GlaxoSmithKline's spinoff plan is hereand it may not be limited to consumer health

As we saw with Flonase, once it becomes over the counter, we have an opportunity to engage a very large patient population and thats exactly what we want to do with Voltaren, Cherian said.

The Arthritis Foundation partnership began with GSK approaching the group to share research and validate its thinking for Voltaren. Thatevolved into the current awareness promotion, with the pre-order and e-commerce idea becoming even more relevant as the COVID-19 pandemic and stay-at-home orders developed.

The rest is here:
GSK partners with Arthritis Foundation as it preps Voltaren for OTC switch - FiercePharma

If you suffer with arthritis, finding a supplement right for you isn't always the easiest task. There's a lot of pills and potions that claim to relieve you of your symptoms, but which ones really work?

Arthritis and other joint conditions affect around 10 million of us in the UK and contrary to popular beliefs, can affect people of all ages.

Osteoarthritis and rheumatoid arthritis are the two most common types and both include symptoms that will cause inflammation, occasional swelling and stiffness of the joints - which over time will become painful and reduce mobility.

Whether you're in the early spectrum of your arthritis or you're just looking for something to manage the pain, there are supplements out there to help and assist with symptoms in the long run.

Before taking any supplement it's always advised to consult with a medical professional first. We've listed top picks worth considering in our roundup below.

Solgar Boswellia Resin Extract capsules are great for many reasons, one being they're nice and inclusive - suitable for vegetarians, vegans and kosher approved.

Boswellia is also known as Indian frankincense, the active components in the extract are widely known for naturally having anti-inflammatory and analgesic properties, it's also been used to treat a number of inflammatory conditions across the globe for centuries.

Some studies have also shown that it may be able to slow the autoimmune process, thus helping to further prevent cartilage loss, which should allow for more freedom in movement that can be comfortably enjoyed.

Price: 15.99, Amazon - buy here now

These supplements are specially formulated for women and are packed full of anti-inflammatory ingredients that will make you feel better from the inside out - at 7 a pop it's not a bad asking price either.

The four main active ingredients in the formula are cayenne, capsicum extract, tumeric and bioperine. Cayenne, capsicum extract, tumeric are all known for their anti-inflammatory and pain reducing properties, whilst the bioperine helps the nutrients to be properly absorbed.

Not only are results seen in the short term, long term pain is reportedly decreased with consistent use too. The tablets are suitable for vegans and vegetarians.

Price: 7, Amazon - buy here now

Cats Claw Cats claw contains a host of active ingredients that can benefit the immune system and overall health.

It's been widely credited by a number of sources to help with joint pain in the long run compared to some of the heavier placebos used to treat inflammatory conditions.

Price: 9.99, Holland and Barrett - buy here now

S-adenosylmethionine, or the lesser mouthful of SAM-e is a natural pain reliever with anti-inflammatory properties, making it a top contender for treating joint related pains.

As well as producing cartilage growth, it's also suggested to affect transmitters that ultimately reduce pain perception, which could be a great benefit for alleviating discomfort long term when it comes to activity.

Price: 18.13, iHerb - buy here now

If you're not ready to give up activity just yet, it's good practice to replenish what you're losing.

Our bodies naturally create glucosamine and chondroitin, they're what form all of the cartilage components, cartilage absorption in the early stage of arthritis is what you'll want to repair and rejuvenate in order to comfortably move around.

If you're running, doing intense training or any activities that might need a little bit of absorption on impact.

Price: 16.55, My Protein - buy here now

The active ingredient in tumeric is curcumin, curcumin has been popular for centuries and is known for its range of health benefits.

Curcumin however, isn't easily absorbed in the body - this fast acting formula from Opti, combines Curcumin with vitamin C in a highly absorbable formula that's hard working, seven times more so than powdered tumeric.

It's a great combination for supporting cartilage formulation and overall joint health.

Price: From: 10.95, Health Span - buy here now

Another hard working duo, these High Strength Glucosamine & Chondroitin Complex capsules help with the overall production of the cartilage and joint tissue, promoting overall joint and immune health.

These tablets also contain MSM, which is a a natural form of organic sulphur that further aids the bodys production of natural glycosaminoglycans.

Price: 12.99, Holland and Barrett - buy here now

If you're looking for the dream trio of anti-inflammatory properties - this supplement from FSC is it.

Ginger is thought to have similar effects to taking an ibruprofen and is used as a home remedy to treat a number of painful ailments.

Packed full of antioxidants and quick-absorbing nutrients that help to promote healing, relieving pain and reducing inflammation in the joints.

The supplement is suitable for vegans.

Price: 9.99, Amazon - buy here now

Fish oil is regularly used as a supplement to treat joint stiffness and inflammation.

Containing 360mg of active EPA/DHA with 25g of vitamin D3, the EPA and DHA are high in Omega-3 - good, fatty acids.

These compounds are converted by our bodies, into powerful chemicals called resolvins which are natural anti-inflammatories, that we just need a bit of help to produce.

Price: 19.99, Holland and Barrett - buy here now

To give yourself and your immune system a fighting chance against sickness, check out the best probiotic supplements to try in 2020.

Originally posted here:
Best supplements for arthritis to try in 2020 - Mirror Online - Mirror Online

Inflammation, although a life-saving immune response, can also range from unpleasant to downright life-threatening. When a body is injured or infected, the white blood cells rush to the affected area to release signaling proteins for protection, while also pushing out potential pathogen, and then start the healing process.

However, blood flow and spark fluid secretions are increased by these proteins, which cause redness, swelling, and pain, which is inflammation. Inflammation is commonly caused by the false identification of harmless substances, even our tissues, by the immune system, which in turn produces painful and often chronic conditions like arthritis, ulcerative colitis, skin conditions, asthma, and general soreness and joint paint.

Mass-market drugs by the dozen are used for the treatment of inflammation, including over-the-counter aspirin, ibuprofen, and naproxen, that although reliable and effective, carry side effects. Furthermore, herbal and natural remedies have also gained popularity in recent years.

However, even the most popular inflammation treatments have their side effects such as ulcers, liver damage, and kidney damage that can be caused by taking high doses of Advil with the active ingredient ibuprofen, over long periods.

Furthermore, fluid retention, high blood pressure, mood, and memory swings, and hormonal imbalance, can be caused by steroids even in the short-term.

Meanwhile, all kinds of inflammation are shown to be alleviated by medical cannabis, which also works in ways that are different from conventional drugs. Cannabis compounds have been shown to suppress cytokines and chemokines the inflammation-causing proteins, unlike the hormone-mimicking steroids and ibuprofen, which works by blocking prostaglandins (released in the brain in response to injury).

National Institutes of Health funded a comprehensive scientific peer review that was published in the journal, Future Science, in 2009, that explained that compounds in cannabis can identify when and where the immune system is over-reacting, and can hence help down-regulate those responses at the site instead of throughout the body.The effectiveness of cannabis in particular for inflammatory bowel disease (IBD), is singled out in the review. This disease, not limited to, can include ulcerative colitis and Chrohns disease.

Regulation of the tissue response to excessive inflammation in the colon has been shown by cannabinoids. The results suggesting the modulation of the physiological activity of the cannabinoid system during colonic inflammation could potentially be a therapeutic tool for the treatment of several diseases.

130 clinical studies that mostly involved lab mice, and similar academic reviews and papers are cited by the review. The review concludes that receptors in the endocannabinoid system, are found on the immune system, which is why cannabinoids can play an important role in the regulation of the immune system.

Despite the promising research, clinical trials involving humans have not been performed. Dr. Sue Sisley, the pioneering medical researcher with a groundbreaking study of cannabis for PTSD, has also shown agreement to the general findings of the 2009 review. Sisleys research, placebo-controlled, blind clinical study that involved more than 70 former US soldiers for their response to cannabis therapy, will help understand the effect of cannabinoids on inflammation in the human body.

According to Sisley, although they have not quantified the degree of anti-inflammation, drawing blood for markers for inflammation, and measuring it pre-treatment and post-treatment, can help see if cannabis has an impact on the inflammatory process.

The results of Sisleys research will not be revealed until it is completed later this year or early next. However, a positive outcome could cause renewed interest in further exploration of the development of cannabis therapies for inflammation, including the different consumption methods, strains, and terpene profiles that will be best suited for certain types of inflammatory response.

However, Sisley has explained although it is believed that strains high in the terpenes Myrceneand Pinene may have the highest anti-inflammatory effects, there is no proper evidence to support this.

Original post:
Does Cannabis Help Patients With Rheumatoid Arthritis? - Cannabis Health Insider

A recent market study on the global Canine Arthritis Treatment market reveals that the global Canine Arthritis Treatment market is expected to reach a value of ~US$ XX by the end of 2029 growing at a CAGR of ~XX% during the forecast period (2019-2029). The impact of the COVID-19 pandemic on the global Canine Arthritis Treatment market is discussed in the presented study.

The Canine Arthritis Treatment market study encloses a thorough analysis of the overall competitive landscape and the company profiles of leading market players involved in the global Canine Arthritis Treatment market. Further, the presented study offers accurate insights pertaining to the different segments of the global Canine Arthritis Treatment market such as the market share, value, revenue, and more.

Request Sample Report @https://www.mrrse.com/sample/17398?source=atm

The following doubts are addressed in the market report:

Key Highlights of the Canine Arthritis Treatment Market Report

The presented report segregates the Canine Arthritis Treatment market into different segments to ensure the readers gain a complete understanding of the different aspects of the Canine Arthritis Treatment market.

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/17398?source=atm

Segmentation of the Canine Arthritis Treatment market

Competitive Outlook

This section of the report throws light on the recent mergers, collaborations, partnerships, and research and development activities within the Canine Arthritis Treatment market on a global scale. Further, a detailed assessment of the pricing, marketing, and product development strategies adopted by leading market players is included in the Canine Arthritis Treatment market report.

The second dominant market in canine arthritis treatment is Germany owing to the rise in prevalence of chronic diseases in animals, particularly dogs. It has been found that with growing age of pets, the prevalence of diseases such as allergies, lower appetite, reduced energy, arthritis, lameness, dysplasia and behavioural anxieties increases, especially in dogs and cats. This growth in terms of pet adoption in European countries and increasing number of pets suffering from arthritis is likely to boost the growth of canine arthritis treatment in Europe. This has been driving the demand for innovative therapies and drugs in Canine Arthritis Treatment, such as stem cell Canine Arthritis Treatment and arthritis drugs NSAIDs and opioids. Canine arthritis treatment/drugs in Germany have taken initiatives to incentivize innovation in the field of veterinary treatment in order to address the urgent need of better veterinary care and to combat rapid growing prevalence of animal diseases. Additionally, increasing expenditure on vet care in high economic European countries such as Germany, France and the U.K. also boosts the growth of the market for canine arthritis treatment. As per the American Pet Products Association, about US$ 6.1 Bn was spent on vet care in 2017 in Europe.

Increasing pet adoption in China and India is expected to drive the growth of the canine arthritis treatment market in Asia-Pacific. In Japan and the Middle East and Africa, the population of dogs is decreasing due to poor vet care facilities, which is expected to hamper the growth of canine arthritis treatment market to some extent.

Buy This Report @ https://www.mrrse.com/checkout/17398?source=atm

See original here:
The impact of the coronavirus on the Canine Arthritis Treatment Market Report Provide the Development Strategies Adopted by Key Industry Players to...

Researchers at Georgia State University have found that auranofin, a drug approved for rheumatoid arthritis, may be an effective treatment against the coronavirus.

The team set out to study how drugs already approved by the Food & Drug Administration interact with the virus, known among scientists as SARS-CoV-2.

Drug repurposing is the fastest way to get a treatment for SARS-CoV-2, because its already been established that these medicines are safe to use in humans, says Mukesh Kumar, lead author of the study, in a press release on GSUs website. Kumar and his colleagues shared their work on bioRxiv for peer review.

Like all viruses, COVID-19 cannot self-reproduce. It needs host cells animal or human in order to make copies of itself.

Effective drugs need to interfere with this replication process, shutting down the virus ability to proliferate inside the host, says Hussin Rothan, a co-author of the study.

With auranofin, the coronavirus was cut down by 95% in human cells within 48 hours, and inflammation caused by the disease was significantly mitigated.

One of the primary causes of death in COVID-19 patients is a syndrome called a cytokine storm, wherein the bodys healing response to illness goes haywire, causing immune cells to attack healthy tissue, leading to organ failure. Cells treated with auranofin, however, saw a significant drop in cytokines, the proteins that signal immune cells to attack.

This shows that the drug not only could inhibit replication of SARS-CoV-2, mitigating the infection, but also reduce the associated lung damage that often leads to severe respiratory distress and even death, says Kumar.

Auranofin, including the brand-name drug Ridaura, was approved by the FDA in 1985. The drug is unique for being partially composed of gold particles, which have been used for centuries for their anti-inflammatory properties. Treatments involving gold compounds have also been considered for use against HIV, cancer, neurodegenerative disorders, and parasitic and bacterial infections.

The team at Georgia State University says they plan to continue their study on how auranofin impacts the coronavirus in animal models.

Read more:
Researchers find rheumatoid arthritis drug is promising coronavirus treatment - New York Post

According to theArthritis Foundation, people with autoimmune or inflammatory arthritis with high disease activity generally have a higher risk of infections due to reduced immune function.

Regarding children with arthritis, the Arthritis Foundation suggests that factors such as arthritis type, disease activity, the involvement of organs, and the level to which their immune system is suppressed may all play a role in the risk of coronavirus infection.

Someresearchsuggests that people with rheumatoid arthritis (RA) have an increased risk of infection because their immune system is impaired. This is typical in autoimmune conditions such as RA.

Furthermore, these people may take medications such as corticosteroids and immunosuppressive drugs that also affect immune function. This may increase their risk of contracting the virus.

The presence of other underlying conditions, such as diabetes or heart disease, can further increase risk.

There is not yet enough evidence to confirm this, but it seems that people with autoimmune or inflammatory arthritis may be at higher risk of infection or severe COVID-19 symptoms.

TheCenters for Disease Control and Prevention (CDC)report that conditions or medications that weaken the immune system increase the risk of severe illness with COVID-19.

Expertssuggest that the main concerns for those with autoimmune conditions who develop COVID-19 include secondary bacterial infections and other complications that may result from the initial viral infection.

In general, those who take immunosuppressive medications, such as biologics or corticosteroids, are at higher risk of a severe viral infection. People who take immunosuppressive medications and who develop flu-like symptoms should call their doctor immediately.

Healthcare professionals typically do not recommend immunosuppressive treatments in those with active infections, but the risk of disease flares is also worth consideration. A person can determine whether to discontinue, taper, or maintain their medication by consulting their doctor.

Those who take immunosuppressive drugs and who do not have symptoms of COVID-19 should discuss their options with their doctor. In some cases, the risk of arthritis flares may outweigh the potential benefits of stopping treatment.

In either case, it is important that people do not adjust their dosage or stop taking their medication without first seeking medical advice.

Visit link:
What To Know About COVID-19 And Arthritis - South Florida Reporter

DUBLIN--(BUSINESS WIRE)--The "Veterinary Orthopedic Implants Market Global Report 2020-30" report has been added to ResearchAndMarkets.com's offering.

The global veterinary orthopedic implants market was worth $98.11 million in 2019. It is expected to grow at a compound annual growth rate (CAGR) of 7.64% and reach $131.71 million by 2023. North America is expected to be the largest for the period 2019-2025.

The increase in the incidence of obesity and arthritis increases the demand for veterinary orthopedic implants market. As reported by Banfield Pet hospital in U.S, in 2017, 31 per 100 cases suffered from obesity and 450 per 10,000 suffered from arthritis in dogs. Further, 34 per 100 cases suffered from obesity and 90 per 10,000 suffered from arthritis in cats. Thus, the increase in health conditions affecting the bones of pets such as obesity and arthritis positively affect the growth of the veterinary orthopedic market.

The high cost of orthopaedic surgery inhibits the growth of veterinary orthopaedic implants market. The surgery cost includes the equipment, X-ray, and consumables among others, which many of the households cannot afford. For instance, in the USA, a typical examination of the problem costs around $400 and the cost of orthopaedic surgery ranges from $1,500 to $4,000. Thus, the high cost of orthopaedic surgery restricts the growth of the veterinary orthopaedic market.

The companies in veterinary orthopaedic implants market are investing in 3D printing technique for creating veterinary orthopaedic implants. 3D printing in veterinary orthopaedics market is being used for creating printed bone models, surgical guides and titanium implants. The use of 3D printing reduces the surgical time, cost and removes the engineering complexities in orthopaedic procedures. Following the trend, many dogs with bone deformities have been treated by Langford Veterinary Services, a UK based provider of veterinary services, through its collaboration with CBM.

The collaboration enabled CBM to create 3D printed models of animal implants using titanium Ti6AI4V EL material. The MRI or CT scans are sent from Langford Veterinary Services in Bristol to CBM who then produces 3D printed models using Arcam EBM Q10plus machine. CBM is a U.K based company focused on advanced research, product development, and batch manufacturing facility. Thus, the use of 3D printing is one of the latest trends in veterinary orthopaedic implants market and will contribute to the growth of the market.

In 2019, Infiniti Medical, a USA based designer and distributor of medical devices for the veterinary market, acquired Orthomed Ltd. for an amount undisclosed. Through the acquisition, Infiniti Medical aims to expand its product portfolio by adding products and services from Orthomed. Orthomed Ltd is a UK based provider of orthopedic products and systems in veterinary industry.

Major players in the market are KYON Pharma, Inc., Veterinary Orthopedic Implants Inc., BioMedtrix, LLC, IMEX Veterinary Inc., Orthomed (UK) Ltd, Securos Surgical, B.Braun Vet Care, Bluesao and DePuy Synthes Vet.

Key Topics Covered

1. Executive Summary

2. Veterinary Orthopedic Implant Market Characteristics

3. Veterinary Orthopedic Implant Market Size And Growth

3.1. Global Veterinary Orthopedic Implant Historic Market, 2015-2019, $ Billion

3.1.1. Drivers Of The Market

3.1.2. Restraints On The Market

3.2. Global Veterinary Orthopedic Implant Forecast Market, 2019-2023F, 2025F, 2030F, $ Billion

3.2.1. Drivers Of The Market

3.2.2. Restraints On the Market

4. Veterinary Orthopedic Implant Market Segmentation

4.1. Global Veterinary Orthopedic Implant Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

4.2. Global Veterinary Orthopedic Implant Market, Segmentation By Animal, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

4.3. Global Veterinary Orthopedic Implant Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

5. Veterinary Orthopedic Implant Market Regional and Country Analysis

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/35hfp1

View post:
Veterinary Orthopedic Implants Market Forecast, 2020-2030 - Increase in Incidence of Obesity and Arthritis is Spurring Demand - ResearchAndMarkets.com...